Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 3Completed 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 19Stomach Neoplasms 12Colorectal Neoplasms 10Rectal Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Esophageal Squamous Cell Carcinoma 5Pancreatic Neoplasms 4Esophageal Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Neoplasm Metastasis 3Nasopharyngeal Carcinoma 3Lung Neoplasms 3Triple Negative Breast Neoplasms 2Endometrial Neoplasms 2Turcot syndrome 1Thyroid Neoplasms 1Squamous Cell Non-small Cell Lung Cancer 1Spinocerebellar Degenerations 1Sarcoma 1Salivary Gland Malignant Neoplasms 1Resectable NSCLC 1Recurrence 1Rare Tumor 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neuroblastoma 1Neoplasms 1NSCLC 1Microsatellite Stable Metastatic Colorectal Cancer 1Metastatic Gastroesophageal Junction Adenocarcinoma 1

Interventions

Gemcitabine 21Cisplatin 16durvalumab 12lenvatinib 11Oxaliplatin 11pembrolizumab 6Liver Transplantation 4Leucovorin 4Floxuridine 4tislelizumab 3Nivolumab 3Magnetic Resonance Spectroscopy 3Folfox protocol 3Fluorouracil 3Drug Therapy 3Capecitabine 3Biopsy 3tremelimumab 2pemigatinib 2olaparib 2ivosidenib 2irinotecan sucrosofate 2apatinib 2Taxes 2Specimen Handling 2Injections 2Immunoglobulin G 2Immune Checkpoint Inhibitors 2Fluorodeoxyglucose F18 2Disulfides 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Cholangiocarcinoma × sintilimab × Clear all
NCT05010681 2025-02-27

Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer

Fudan University

Phase 2 Recruiting
25 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡